Status:
TERMINATED
Study of XL999 in Patients With Previously Treated Ovarian Cancer
Lead Sponsor:
Symphony Evolution, Inc.
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated ...
Eligibility Criteria
Inclusion
- Female patients with a histologically confirmed diagnosis of metastatic ovarian cancer
- Measurable disease according to Response Criteria for Solid Tumors (RECIST)
- Prior treatment with platinum-based therapy
- Platinum-sensitive or platinum-resistant disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of ≥3 months
- Adequate organ and marrow function
- Signed informed consent
- No other malignancies within 5 years
Exclusion
- Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
- Use of an investigational drug or cytotoxic chemotherapy within 30 days of XL999 treatment
- Prior anticancer therapy targeting VEGF (eg, bevacizumab, sorafenib, or sunitinib)
- More than two prior systemic non-platinum cytotoxic chemotherapy regimens
- Subject has not recovered to grade ≤1 or to within 10% of baseline from adverse events due to other medications administered \>30 days prior to study enrollment
- History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
- Uncontrolled and/or intercurrent illness
- Patients who are pregnant or breastfeeding
- Known human immunodeficiency virus (HIV)
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00277290
Start Date
January 1 2006
End Date
November 1 2006
Last Update
February 22 2010
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
California Cancer Care, Inc.
Greenbrae, California, United States, 94904
2
Hematology/Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States, 34952
3
University of Chicago
Chicago, Illinois, United States, 60637
4
Joliet Oncology-Hematology Associates, Ltd
Joliet, Illinois, United States, 60435